A Study of MEDI-575 in Patients With Advanced Solid Malignancies

Phase 1 Completed 22 enrolled AstraZeneca MedImmune LLC · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).

Timeline

Start: 2010-03
Primary completion: 2012-11
Completion: 2012-11

Publications

Murakami H, Ikeda M, Okusaka T, Inaba Y, Iguchi H, Yagawa K, Yamamoto N. A Phase I study of MEDI-575, a PDGFRalpha monoclonal antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Sep;76(3):631-9. doi: 10.1007/s00280-015-2832-6. Epub 2015 Jul 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TOVETUMAB	Monoclonal antibody	9 mg/kg	Intravenous
Subject	TOVETUMAB	Monoclonal antibody	15 mg/kg	Intravenous
Subject	TOVETUMAB	Monoclonal antibody	25 mg/kg	Intravenous
Subject	TOVETUMAB	Monoclonal antibody	35 mg/kg	Intravenous

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

Summary

Timeline

Publications

Drugs

Indications